Topics

Bactevo Company Profile

04:15 EST 24th January 2020 | BioPortfolio

Bactevo has built a unique and game-changing Totally Integrated Medicines Engine (TIME) to create novel therapeutics. Utilising its paradigm shift in the speed, efficiency and quality of drug discovery, as well as massively enhancing safety profiling to improve clinical success, Bactevo is developing breakthrough medicines for the treatment of diseases that involve defects in mitochondrial function, such as MELAS and LHON, as well as diseases of the central nervous system, such as Parkinson’s, Alzheimer’s and Amyotrophic Lateral Sclerosis (ALS). Further information can be found at www.bactevo.com.


News Articles [0 Results]

None

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [2 Associated Companies listed on BioPortfolio]

Bactevo

Bactevo has built a unique and game-changing Totally Integrated Medicines Engine (TIME) to create novel therapeutics. Utilising its paradigm shift in the speed, efficiency and qua...

Bactevo Ltd.

Bactevo has built a unique, game-changing Totally Integrated Medicines Engine (TIME) to create novel therapeutics. Enabled by advance machine learning, TIME utilises its paradigm ...

More Information about "Bactevo" on BioPortfolio

We have published hundreds of Bactevo news stories on BioPortfolio along with dozens of Bactevo Clinical Trials and PubMed Articles about Bactevo for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Bactevo Companies in our database. You can also find out about relevant Bactevo Drugs and Medications on this site too.

Quick Search

Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Parkinson's Disease
Parkinson's is a progressive neurological condition, affecting one person in every 500, 95% of which are over 40. It is caused by degeneration of more than 70% of the substantia nigra, which depletes the dopamine (the neurotransmitter involved in pro...


Corporate Database Quicklinks



Searches Linking to this Company Record